drugset / Trial / NCT05601440
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is being done to answer the following question: Can testing breast cancer for DNA abnormalities or "biomarkers" help predict which patients are most likely to be helped by certain treatments? The pre-study screening is being done to test a sample of blood (or tumour tissue) for biomarkers to see if patients can participate in the study
Timeline
- Start
- 2023-06-13
- Primary completion
- 2027-12-31
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camonsertib | Small molecule | — | — |
| Subject | Fulvestrant | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | LUVIXASERTIB | Small molecule | — | — |
| Subject | Lunresertib | Small molecule | — | — |
| Subject | Niraparib | Small molecule | — | — |
| Subject | OCIFISERTIB | Small molecule | — | — |
| Subject | Sacituzumab Govitecan | Monoclonal antibody | — | — |